Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
BIOASIS ANNOUNCES ANALYST COVERAGE INITIATED BY ZACKS INVESTMENT RESEARCH
BIOASIS ANNOUNCES ANALYST COVERAGE INITIATED BY ZACKS INVESTMENT RESEARCH
GUILFORD, CONN., BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF;), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that John D. Vandermosten, CFA, Biotechnology Analyst of Zacks Small Cap Research division at Zacks Investment Research and his team (“Zacks”) has initiated analyst coverage on Bioasis Technologies Inc.
A copy of the research report may be obtained directly from the analyst at Zacks by contacting Mr. Vandermosten, on +1.312.265.9588 or at jvandermosten@zacks.com or by contacting the Zacks Small Cap Research team at scr@zacks.com.
